Brenzavvy

Brenzavvy is the brand name for bexagliflozin. It is an effective agent for improving glycemic control (blood sugar levels) in adults with type 2 diabetes mellitus. Brenzavvy operates by targeting the sodium-glucose co-transporter 2 (SGLT2) in the kidneys. This action leads to the excretion of excess glucose in the urine, effectively lowering blood sugar levels. Patients with chronic conditions like type 2 diabetes often turn to Brenzavvy as part of a comprehensive management plan involving diet and exercise.

Note: This medication’s generic and brand-name formulations are used interchangeably throughout this article.

Brenzavvy is primarily used as an adjunct to diet and exercise to treat and manage chronic type 2 diabetes mellitus. Its therapeutic use focuses on improving glycemic control.

Primary Indications

• Improve glycemic control in adults with type 2 diabetes mellitus: Brenzavvy is used to help manage high blood sugar, a key factor in the progression of type 2 diabetes and the risk of associated complications.

Understanding how Brenzavvy operates provides greater insight into its therapeutic effects and its role in diabetes care. The drug’s active ingredient, bexagliflozin, acts at the cellular level in the kidneys.

Mechanism of Action

Brenzavvy’s primary mechanism is to inhibit sodium-glucose co-transporter 2 (SGLT2), a protein responsible for reabsorbing the majority of filtered glucose from the bloodstream back into the body within the renal proximal tubule.

By blocking this transporter, Brenzavvy:

• Reduces the renal reabsorption of filtered glucose.
• Lowers the renal threshold for glucose.
• Increases urinary glucose excretion (UGE), thereby lowering blood glucose concentrations.

Pharmacokinetics

Bexagliflozin is well absorbed orally, with peak plasma concentrations (Cmax) reached between 2 and 4 hours post-dose. It is approximately 93% bound to plasma protein. The drug is mainly metabolized in the liver by UGT1A9 and, to a lesser extent, CYP3A. The terminal elimination half-life is approximately 12 hours. Elimination occurs primarily through feces and urine.

Proper dosing and administration of Brenzavvy are vital to maximize its therapeutic benefits while minimizing potential risks.

Dosage Recommendations

• The recommended dosage of Brenzavvy is 20 mg orally taken once daily in the morning, with or without food.
• The dosage is the same for patients with normal renal function and those with mild to moderate hepatic impairment.
• Brenzavvy is not recommended in patients with an estimated glomerular filtration rate (eGFR) less than 30 mL/min/1.73 m².

Administration Guidelines

• Brenzavvy should be taken orally, with or without food, but maintaining a consistent morning dosing schedule is important.
• Patients must not crush or chew the tablet.
• If a dose is missed, take it as soon as possible. Do not double the next dose.
• Volume status and renal function should be assessed before initiating therapy, particularly in patients with impaired renal function, the elderly, those with low systolic blood pressure, or patients on diuretics, with volume depletion corrected prior to starting Brenzavvy.

While Brenzavvy is effective in treating type 2 diabetes, like any medication, it comes with potential side effects and risks.

Common Side Effects (Incidence > 5%)

• Female genital mycotic infections
• Urinary tract infection
• Increased urination (which can include polyuria, pollakiuria, micturition urgency, and nocturia)

Serious Warnings and Risks

While less common, these serious conditions warrant immediate medical attention:

• Ketoacidosis: A serious, life-threatening condition that may occur even when blood glucose levels are below 250 mg/dL. If signs of severe metabolic acidosis occur, discontinue Brenzavvy and seek immediate medical evaluation.
• Lower Limb Amputation: An increased risk has been observed in some trials. Patients should be monitored for signs and symptoms of infection or ulcers of the lower limbs, and Brenzavvy should be discontinued if these complications occur. Routine preventative foot care is important.
• Volume Depletion (Dehydration): May lead to symptomatic hypotension or acute kidney injury. Monitoring for signs and symptoms of volume depletion is required during therapy.
• Urosepsis and Pyelonephritis: Serious urinary tract infections that may require hospitalization have been reported. Patients must be evaluated for signs and symptoms of urinary tract infections and treated promptly.
• Necrotizing Fasciitis of the Perineum (Fournier’s Gangrene): A rare but serious and life-threatening infection. If suspected (pain, tenderness, erythema, or swelling in the genital/perineal area, along with fever), discontinue the drug and institute prompt surgical and antibiotic treatment.
• Hypoglycemia: The risk of low blood sugar increases when Brenzavvy is used with insulin or an insulin secretagogue (such as a sulfonylurea). A dose reduction of the concomitant medication may be necessary.
• Genital Mycotic Infections: Monitor patients for these infections and treat appropriately.
• Fractures: An imbalance in serious fractures was observed in a cardiovascular risk trial.

Brenzavvy interacts with various other substances, which can influence its effectiveness and safety profile.

Primary Drug Interactions

• UGT Enzyme Inducers (e.g., Rifampin): These drugs can significantly reduce bexagliflozin exposure, leading to decreased efficacy. Consideration should be given to adding another antihyperglycemic agent.
• Insulin and Insulin Secretagogues: Hypoglycemia risk increases. A lower dose of the insulin or secretagogue may be needed.
• Lithium: Concomitant use may decrease serum lithium concentrations. Serum lithium concentration should be monitored more frequently upon Brenzavvy initiation and discontinuation.

Laboratory Interference

• Positive Urine Glucose Test: Brenzavvy increases urinary glucose excretion, resulting in a positive test result. Urine glucose tests are not recommended for monitoring glycemic control in patients taking SGLT2 inhibitors.
• 1,5-Anhydroglucitol (1,5-AG) Assay: Measurements of 1,5-AG are unreliable in assessing glycemic control. Alternative methods should be used.